Michaela Mattheus

Area of research

Endocrinology, Diabetes and Metabolism · Surgery

Research interest

Research focused on Empagliflozin and Myocardial infarction, with related work in Diuretic, Hazard ratio, Renal function. Notable publications include 'Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes', 'Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes', and 'Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG...'.

Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial

Circulation 2024cited by 87position: middledoi

Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction

Journal of the American College of Cardiology 2024cited by 33position: middledoi

Early Changes in Estimated Glomerular Filtration Rate Post-Initiation of Empagliflozin in EMPEROR-Preserved

European Journal of Heart Failure 2024cited by 25position: middledoi

Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial

Cardiovascular Diabetology 2024cited by 11position: middledoi

BMI variability and cardiovascular outcomes within clinical trial and real-world environments in type 2 diabetes: an IMI2 SOPHIA study

Cardiovascular Diabetology 2024cited by 11position: middledoi

Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in <scp>EMPEROR‐Reduced</scp>

European Journal of Heart Failure 2022cited by 42position: middledoi

The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and <scp>non‐Asian</scp> populations of the <scp>EMPA‐REG OUTCOME</scp> trial of patients with type 2 diabetes and cardiovascular disease

Diabetes Obesity and Metabolism 2021cited by 20position: middledoi

Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

Kidney International 2020cited by 208position: middledoi

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

The Lancet Diabetes & Endocrinology 2020cited by 70position: middledoi

The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus

Journal of the American Society of Hypertension 2017cited by 97position: middledoi

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

New England Journal of Medicine 2016cited by 3,602position: middledoi

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

Clinical Therapeutics 2016cited by 87position: middledoi

Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus

Clinical Therapeutics 2016cited by 57position: middledoi

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

New England Journal of Medicine 2015cited by 11,886position: middledoi

Recent publications

Grants

Frequent collaborators